Hantz Financial Services’s Apellis Pharmaceuticals APLS Stock Holding History

Hantz Financial Services’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,836	Closed	-$114K	–	2464
2026 Q1	$114K	Buy	+2,836	New	+$61.1K	﹤0.01%	1243
2025 Q2	–	Sell	-6	Closed	–	–	2177
2025 Q1	$0	Buy	+6	New	+$166	﹤0.01%	1675

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hantz Financial Services's APLS Position: Q2 2026 in Review

Hantz Financial Services sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 2,836 shares — an estimated $114K sold.

Hantz Financial Services first reported a position in APLS in Q1 2025 and held it in 2 quarters. The position peaked at $114K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Hantz Financial Services reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Hantz Financial Services sold 2,836 Apellis Pharmaceuticals shares in Q2 2026, an estimated $114K.
Hantz Financial Services first reported a position in Apellis Pharmaceuticals in Q1 2025 and held it in 2 quarters.
Hantz Financial Services's Apellis Pharmaceuticals position peaked at $114K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.